Short answer · Medically reviewed summary · Last updated: 2026-05-08
CLOVES syndrome is a rare overgrowth disorder caused by somatic PIK3CA mutations, and while there is no cure, the prognosis has significantly improved with the emergence of targeted PI3K inhibitor therapies. Long-term outcomes for those with CLOVES syndrome vary widely depending on the severity of vascular malformations and the extent of tissue overgrowth, but proactive, multidisciplinary care allows many individuals to achieve a good quality of life. What determines the long-term prognosis for CLOVES syndrome? The prognosis for CLOVES syndrome depends heavily on the specific manifestations present, such as the size and location of lipomatous masses, the severity of scoliosis, and the nature of vascular anomalies.
Cloves Syndrome prognosis
Prognosis of Cloves Syndrome: quality of life, limitations and outlook, from research and from people who live with it.
CLOVES syndrome is a rare overgrowth disorder caused by somatic PIK3CA mutations, and while there is no cure, the prognosis has significantly improved with the emergence of targeted PI3K inhibitor therapies. Long-term outcomes for those with CLOVES syndrome vary widely depending on the severity of vascular malformations and the extent of tissue overgrowth, but proactive, multidisciplinary care allows many individuals to achieve a good quality of life.
What determines the long-term prognosis for CLOVES syndrome?
The prognosis for CLOVES syndrome depends heavily on the specific manifestations present, such as the size and location of lipomatous masses, the severity of scoliosis, and the nature of vascular anomalies. Because CLOVES syndrome is a mosaic condition, the clinical presentation is highly variable; some individuals experience mild symptoms, while others face significant mobility challenges or chronic pain. Early intervention is the most critical factor in improving long-term outcomes.
How has modern medicine changed outcomes for CLOVES syndrome?
In the past, management of CLOVES syndrome was largely limited to orthopedic surgery and debulking procedures, which often carried high risks of recurrence. Today, the introduction of PI3K inhibitors, such as alpelisib, has revolutionized the management of CLOVES syndrome. These medications target the underlying genetic pathway, often leading to a reduction in the size of vascular malformations and fatty overgrowth, thereby reducing the need for invasive surgeries.
What complications should patients with CLOVES syndrome monitor?
Due to the complex nature of the disorder, individuals with CLOVES syndrome require vigilant monitoring for several potential complications:
- Progressive spinal deformities such as scoliosis or kyphosis.
- Deep vein thrombosis (DVT) and pulmonary embolism risks linked to vascular malformations.
- Chronic pain management due to nerve compression or tissue overgrowth.
- Coagulopathy issues related to complex vascular anomalies.
- Developmental delays or seizures, which occur in a subset of patients with brain involvement.
Next steps
- Consult a specialized multidisciplinary team, typically including a geneticist, pediatric surgeon, and hematologist.
- Join the 7 members of the DiseaseMaps.org community to share experiences and coping strategies.
- Discuss targeted PI3K inhibitor therapy with your specialist to see if you are a candidate.
- Ensure regular screening for orthopedic and vascular progression to address issues before they become acute.
Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): CLOVES syndrome overview.
- Orphanet: Rare disease database entry for CLOVES syndrome (ORPHA:261245).
- OMIM (Online Mendelian Inheritance in Man): Entry #612918 regarding PIK3CA-related overgrowth spectrum.
- The CLOVES Syndrome Community: Patient-led resources and clinical research updates.
